Professor Amanda Tufman is a thoracic oncologist specialising in understanding the molecular mechanisms underlying thoracic cancers and developing innovative therapeutic strategies.

 

Professor Tufman’s clinical work includes cutting-edge research into the molecular biology of lung cancer.  Her work involves developing targeted therapies and personalised medicine strategies aimed at improving the prognosis for patients with lung cancer, particularly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Her research focuses on the genetic mutations that drive these cancers and the ways in which targeted therapies can address specific vulnerabilities in cancer cells.

 

Professor Tufman has also been at the forefront of improving early detection methods for lung cancer, emphasizing the importance of early intervention in improving survival rates. Her work in this area has led to advancements in imaging techniques, biomarkers, and screening programs that aid in identifying lung cancer at an earlier and more treatable stage.

 

In addition to her clinical and academic roles, Professor Tufman is an active member of numerous international oncology societies. She has served on editorial boards for several medical journals, contributed to influential publications, and participated in various international conferences and symposia.

Prof. Amanda Tufman has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Celgene, Lilly, MSD, Novartis, Pierre Fabre Laboratoires, Roche, Takeda

 

Grant - Astrazeneca (need to differentiate EW?)